GRAFT POLYMER (UK) PLC

Regulatory Filings • Oct 15, 2024

National Storage Mechanism | Additional information

RNS Number : 1363I

Graft Polymer (UK) PLC

15 October 2024

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

15 October 2024

Graft Polymer (UK) Plc

(the "Company")

Research agreement with the University of Nottingham

Graft Polymer (UK) Plc (LON: GPL) (the "Company"), an innovative biotechnology company co-developing therapeutics for mental health disorders, announces that its partner, Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF) ("Awakn"), has entered a research agreement with the University of Nottingham. The research will be conducted in vivo and will evaluate the potential of the Company and Awakn's  aminoindane  new chemical entity ("NCE") co-lead series to enhance social cognition and pro-social behaviors, a critical step in developing a new class of medicines for treating trauma-related disorders such as Post-Traumatic Stress Disorder ("PTSD").

The research will be led by Dr. Madeleine King, Assistant Professor in the Faculty of Medicine & Health Sciences at the University of Nottingham, which is recognised globally for its cutting-edge neuroscience research. Dr. King brings over 20 years of experience in behavioral neuroscience, focusing on psychiatric disorder research. The research will employ the Social Transmission of Food Preferences ("STFP") test in rodent models and is expected to run over two months, with results due by the end of 2024.

This in vivo research represents a significant step in the Company's NCE programme, which is being developed under a collaboration agreement with Awakn. The programme is focused on developing next-generation therapeutics for mental health disorders, including PTSD, a condition affecting over 13 million adults in the U.S. and 20 million across the U.S., UK, and Europe.

Anthony Tennyson, CEO of Graft Polymer, commented: "This is a significant step forward in our joint programme with Awakn. The in vivo testing at the University of Nottingham will be pivotal in assessing the therapeutic potential of our novel aminoindane compounds, bringing us closer to addressing the unmet needs in trauma-related mental health disorders."

Dr Madeline King, from the School of Life Sciences at the University of Nottingham said: "I'm delighted that Awakn Life Sciences have chosen to collaborate with the University of Nottingham.  I'm excited to be involved in this research, which has real potential to improve patient health."

Enquiries:

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director. anthonytennyson@graftpolymer.co.uk

Allenby Capital (Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

About Graft Polymer (UK) Plc

Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders.  Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affects approximately 13 million adults in the U.S. and 20 million in US, UK, and key EU  markets.

For more information, please visit www.graftpolymer.co.uk .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RESBRBDGSBBDGSS